FrancophonIA/ELRC3.0 huggingface dataset:
English: SAPPHIRE-I - genotype 1, treatment-naïve, without cirrhosis
Danish: SAPPHIRE I - genotype 1, behandlingsnaive, uden cirrose Design:
English: Genotype 1a, with compensated cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
Danish: Genotype 1a, med kompenseret cirrose dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
English: Mechanism: possibly due to UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Danish: Mekanisme: Skyldes muligvis paritaprevir, ombitasvir og dasabuvirs hæmning af UGT
English: 5 mg single dose
Danish: 5 mg enkeltdosis
English: buprenorphin e/ naloxone 4-24 mg/16 mg once daily8
Danish: 4-24 mg/16 mg én gang dagligt8
English: Poly(vinyl alcohol) (E 1203) Titanium dioxide (E 171) Macrogol (3350) Talc (E 553b)
Danish: Filmovertræk Polyvinylalkohol (E 1203) Titaniumdioxid (E 171) Macrogol (3350) Talkum (E553b) Gul jernoxid (E 172) Rød jernoxid (E 172) Sort jernoxid (E 172)
English: TURQUOISE-III: treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis
Danish: TURQUOISE-III: behandlingsnaive eller pegIFN + RBV-erfarne med kompenseret cirrose Design:
English: PEARL-II - genotype 1b, pegIFN+RBV-experienced, without cirrhosis Design:
Danish: PEARL II - genotype 1b, pegIFN + RBV-erfarne, uden cirrose
English: multicentre, open-label
Danish: åbent, multicenter
English: ↑ rilpivirine
Danish: ↑ rilpivirin
English: ↑ norbu prenorphine
Danish: ↑ norbupre norphin
English: Dasabuvir safety and efficacy have been established in combination with ombitasvir/ paritaprevir /ritonavir with or without ribavirin.
Danish: Sikkerheden ved og virkningen af dasabuvir i kombination med ombitasvir/paritaprevir/ritonavir (sammen med eller uden ribavirin) er blevet klarlagt.
English: SVR12 for genotype 1-infected treatment-naïve subjects in SAPPHIRE-I
Danish: SVR12 for behandlingsnaive genotype 1-smittede forsøgspersoner i SAPPHIRE I
English: Other pegIFN/RBV failures
Danish: Tidligere ikke-respondere på pegIFN/RBV
English: For contra-indications with ombitasvir/ paritaprevir /ritonavir refer to the Summary of Product Characteristics.
Danish: For kontraindikationer med ombitasvir/paritaprevir/ritonavir, se produktresuméerne.
English: Ethinyloestradiol containing oral contraceptives are contraindicated (see section 4.3).
Danish: Ethinyløstradiol-holdige præventionsmidler er kontraindicerede (se pkt.
English: 0.5 mg single dose
Danish: 0,5 mg enkeltdosis
English: Serum ALT elevations
Danish: Forhøjet ALAT i serum
English: randomised, global multicentre, open-label
Danish: randomiseret, globalt multicenter studie, åbent
English: 400 mg once daily
Danish: 400 mg en gang dagligt
English: Treated subjects (N=419) had a median age of 50 years (range: 19 to 70); 45.8% were male; 4.8% were Black; 9.3% had a history of depression or bipolar disorder; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Danish: De behandlede patienter (N = 419) havde en median alder på 50 år (interval: 19-70); 45,8 % var mænd; 4,8 % var sorte; 9,3 % havde depression eller bipolar lidelse i anamnesen; 73,3 % havde et HCV-rna-niveau på mindst 800.000 IE/ml ved baseline; 20,3 % havde portal fibrose (F2), og 10,0 % havde bridging fibrose (F3).
English: 40 mg once daily
Danish: 40 mg én gang dagligt
English: ombitasvir/paritaprevir/ritonavir with or without dasabuvir coadminstered with or without weight-based ribavirin for 12 or 24 weeks
Danish: Behandling: ombitasvir/paritaprevir/ritonavir med eller uden dasabuvir administreret samtidig med eller uden ribavirin baseret på vægt i 12 eller 24 uger
English: TURQUOISE-I: treatment-naïve or pegIFN + RBV-experienced with HCV GT1 or GT4/HIV-1 coinfection, without cirrhosis or with compensated cirrhosis
Danish: TURQUOISE-I: behandlingsnaive eller pegIFN + RBV-erfarne med samtidig hiv-1 infektion, uden eller med kompenseret cirrose
English: Mechanism: CYP3A inhibition by ritonavir.
Danish: Mekanisme: Ritonavirs hæmning af CYP3A.
English: 50 mg once daily
Danish: 50 mg en gang dagligt
English: For interactions with ombitasvir/ paritaprevir /ritonavir refer to the Summary of Product Characteristics.
Danish: For interaktioner med ombitasvir/ paritaprevir /ritonavir, se produktresuméerne.
English: For dosing recommendations with HIV antiviral medicinal products, refer to sections 4.4 and 4.5.
Danish: Hvad angår doseringsanbefalinger for antivirale lægemidler mod hiv, henvises til pkt.
English: HIV coinfected patients without suppressive antiretroviral therapy should not be treated with dasabuvir.
Danish: Patienter, der samtidig er hiv-smittede, og som ikke får supprimerende antiretroviral behandling, må ikke behandles med dasabuvir.Hos patienter med samtidig hiv-infektion skal der tages nøje højde for lægemiddelinteraktioner (se nærmere i pkt.
English: 9% had advanced fibrosis (F3) and 98.2% had HCV genotype 1b infection (one subject each had genotype 1a, 1d, and 6 infection).
Danish: havde bridging fibrose (F3); 67,7 % havde HCV genotype 1a-infektion; 32,3 % havde HCV genotype 1b-infektion.
English: Mechanism: OATP1B1 inhibition by paritaprevir.
Danish: Mekanisme: Paritaprevirs hæmning af OATP1B1.
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir
Danish: Gruppe A: Dasabuvir og ombitasvir/paritaprevir/ritonavir + RBV Gruppe B: Dasabuvir og ombitasvir/paritaprevir/ritonavir
English: SVR12 for genotype 1b-infected treatment-naïve subjects in PEARL III
Danish: SVR12 for behandlingsnaive genotype 1b-smittede forsøgspersoner i PEARL III
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV Arm B: Placebo
Danish: Gruppe A: Dasabuvir og ombitasvir/paritaprevir/ritonavir + RBV Gruppe B: Placebo
English: SVR12 for genotype 1a-infected treatment-naïve subjects in PEARL IV
Danish: SVR12 for behandlingsnaive genotype 1a-smittede forsøgspersoner i PEARL IV
English: Laboratory abnormalities
Danish: Unormale laboratorieværdier
English: SVR12 for genotype 1b-infected peginterferon+ribavirin-experienced subjects in PEARL II
Danish: SVR12 for peginterferon/ribavirin-erfarne genotype 1b-smittede forsøgspersoner i PEARL II
English: Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV (24 weeks)
Danish: Gruppe B: Dasabuvir og ombitasvir/paritaprevir/ritonavir + RBV (24 uger)
English: Concomitant use is contraindicated (see
Danish: Ikke relevant Samtidig brug er kontraindiceret (se pkt.
English: 600 mg twice daily
Danish: 600 mg to gange dagligt
English: Genotype 1b, without cirrhosis or with compensated cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir
Danish: Genotype 1b, uden cirrose eller med kompenseret cirrose dasabuvir + ombitasvir/paritaprevir/ritonavir
English: HCV Genotype 1a dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV
Danish: HCV genotype 1a Dasabuvir og ombitasvir/paritaprevir/ritonavir med RBV
English: Note: For laboratory abnormalities refer to Table 4.
Danish: Bemærk: I tabel 4 er der en oversigt over unormale laboratorieværdier.
English: Prior pegIFN/RBV relapser
Danish: Tidligere delvise respondere på pegIFN/RBV
English: Mechanism: decrease possibly due to CYP1A2 induction by ritonavir dasabu vir +
Danish: Mekanisme: Reduceret cyclobenzapri n-eksponering skyldes muligvis ritonavirs inducerende virkning på CYP1A2
English: Mechanism: OATP1B inhibition by paritaprevir.
Danish: Pitavastatin Mekanisme: Paritaprevirs hæmning af OATP1B.
English: PEARL-IV - genotype 1a, treatment-naïve, without cirrhosis
Danish: PEARL IV - genotype 1a, behandlingsnaive, uden cirrose Design:
English: TURQUOISE-II: relapse rates by baseline laboratory values after 12 and 24 weeks of treatment in subjects with genotype 1a infection and compensated cirrhosis dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV 12-week arm dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV 24-week arm
Danish: TURQUOISE II: Recidivrate ud fra laboratorieværdier ved baseline efter 12 og 24 ugers behandling hos patienter med genotype 1a-infektion og kompenseret cirrose
English: Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Danish: De behandlede patienter (N = 380) havde en median alder på 58 år (interval: 21-71); 42,1 % var behandlingsnaive, 36,1 % var tidligere ikke-respondere på pegIFN/RBV; 8,2 % var tidligere delvise respondere på pegIFN/RBV, 13,7 % var patienter med tidligere recidiv efter pegIFN/RBV-behandling; 70,3 % var mænd; 3,2 % var sorte; 14,7 % havde et trombocyttal på under 90 x 109/l; 49,7 % havde et albuminniveau på under 40 g/l; 86,1 % havde et HCV-rna-niveau på mindst 800.000 IE/ml ved baseline; 24,7 % havde depression eller bipolar lidelse i anamnesen; 68,7 % havde HCV genotype 1ainfektion, 31,3 % havde HCV genotype 1b-infektion.
English: Concomitant use of tacrolimus with dasabuvir and ombitasvir/paritaprevir/ ritonavir is not recommended unless the benefits outweigh dasabuvir ombitasvir
Danish: Samtidig brug af tacrolimus med dasabuvir og ombitasvir/paritaprevir/ri tonavir anbefales ikke, medmindre fordelene
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV
Danish: Gruppe A: Dasabuvir og ombitasvir/paritaprevir/ritonavir + RBV
English: Mechanism: CYP3A4 inhibition by ritonavir and UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Danish: Mekanisme: Ritonavirs hæmning af CYP3A4 samt paritaprevir, ombitasvir og dasabuvirs hæmning af UGT.
English: Dose normalized cyclosporine ratios are shown for interaction with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Danish: Dosisnormaliserede ciclosporin-ratioer er vist for interaktionen med dasabuvir + ombitasvir/paritaprevir/ritonavir.
English: Dose normalized sirolimus ratios are shown for interaction with ombitasvir/paritaprevir/ritonavir + dasabuvir.
Danish: Dosisnormaliserede sirolimus -ratioer er vist for interaktion med ombitasvir/paritaprevir/ritonavir + dasabuvir.
English: Dose normalized tacrolimus ratios are shown for interaction with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Danish: Dosisnormaliserede tacrolimus-ratioer er vist for interaktionen med dasabuvir + ombitasvir/paritaprevir/ritonavir.
English: paritaprevir the risks (see section
Danish: paritaprevir opvejer risiciene (se pkt 4.4).
English: Endpoint dasabuvir and ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 or 24 Weeks N = 200a
Danish: Dasabuvir og ombitasvir/paritaprevir/ritonavir med eller uden ribavirin i 12 eller 24 uger N = 200a
English: Refer to the Summary of Product Characteristics of ombitasvir/paritaprevir/ritonavir for its pharmacological properties.
Danish: Se beskrivelsen af de farmakologiske egenskaber i produktresuméet for ombitasvir/paritaprevir/ritonavir.
English: This will give the medicines the best chance to clear the hepatitis C virus infection.
Danish: Det er meget vigtigt, at du gennemfører hele behandlingsforløbet, så lægemidlet kan virke optimalt og fjerne din hepatitis Cvirusinfektion.
English: Hepatic impairment
Danish: DIURETIKA Furosemid
English: Mechanism: possibly due to UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Danish: Mekanisme: Skyldes muligvis paritaprevir, ombitasvir og dasabuvirs hæmning af UGT1A1.
English: If you have any questions about your medicines, please ask your doctor or pharmacist.
Danish: Er du i tvivl, så spørg lægen eller på apoteket.
English: Prior pegIFN/RBV null responder Prior pegIFN/RBV partial responder Prior pegIFN/RBV relapser Outcome for subjects without SVR12 On-treatment VF
Danish: Tidligere ikke-respondere på pegIFN/RBV 56/59 Tidligere delvise respondere på pegIFN/RBV 28/28 Patienter med tidligere recidiv efter pegIFN/RBV-behandling
English: Uncommon: may affect up to 1 in 100 people
Danish: Ikke almindelige bivirkninger: forekommer hos op til 1 ud af 100 behandlede:
English: Mechanism: possibly due to UGT1A1 inhibition by paritaprevir, dasabuvir and ombitasvir and CYP3A4 inhibition by ritonavir dasabuvi r + ombitas vir/parit aprevir/r itonavir dolutegravir
Danish: Mekanisme: Skyldes muligvis paritaprevir, dasabuvir og ombitasvirs hæmning af UGT1A1 og ritonavirs hæmning af CYP3A4
English: ↑ bu prenorphine
Danish: ↑ buprenor phin
English: Treated subjects (N = 22) had a median age of 54 years (range: 34 to 68); 41% were Black; 14% had compensated cirrhosis; 86% were HCV treatment-naïve; 14% had failed prior treatment with pegIFN/RBV; 68% had HCV genotype 1a infection.
Danish: (interval: 34-68), 41 % var sorte, 14 % havde kompenseret cirrose, 86 % var HCV-behandlingsnaive, 14 % havde oplevet behandlingssvigt med pegIFN/RBV, og 68 % havde HCV genotype 1a-infektion.
English: Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 20.6% had a history of depression or bipolar disorder; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Danish: De behandlede patienter (N = 394) havde en median alder på 54 år (interval: 19-71); 49,0 % var tidligere ikke-respondere på pegIFN/RBV; 21,8 % var tidligere delvise respondere på pegIFN/RBV, og 29,2 % var patienter med tidligere recidiv efter pegIFN/RBV-behandling; 57,6 % var mænd; 8,1 % var sorte; 20,6 % havde depression eller bipolar lidelse i anamnesen;; 87,1 % havde et HCV-rnaniveau på mindst 800.000 IE/ml ved baseline; 17,8 % havde portal fibrose (F2), og 14,5 % havde bridging fibrose (F3); 58,4 % havde HCV genotype 1a-infektion; 41,4 % havde HCV genotype 1binfektion.
English: No dose adjustment is necessary for emtricitabine/tenofovir and dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Danish: Dosisjustering er ikke nødvendig for emtricitabin/tenofovir og dasabuvir med ombitasvir/ paritaprevir/ritonavir.
English: 400 mg twice daily
Danish: 400 mg to gange dagligt
English: ombitas vir/parit aprevir/r itonavir cyclobenzap rine
Danish: Dasabuvir + ombitasvir/p aritaprevir/ri tonavir cyclobenzap rin
English: Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders; and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; ; 12.8% had a history of depression or bipolar disorder; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Danish: De behandlede patienter (N = 179) havde en median alder på 57 år (interval: 26-70); 35,2 % var tidligere ikke-respondere på pegIFN/RBV; 28,5 % var tidligere delvise respondere på pegIFN/RBV, og 36,3 % var patienter med tidligere recidiv efter pegIFN/RBV-behandling; 54,2 % var mænd; 3,9 % var sorte; 12,8 % havde depression eller bipolar lidelse i anamnesen; 87,7 % havde et HCV-rnaniveau på mindst 800.000 IE/ml ved baseline; 17,9 % havde portal fibrose (F2), og 14,0 % havde bridging-fibrose (F3).
English: Mechanism: CYP3A4 induction by phenytoin.
Danish: Mekanisme: Phenytoins inducerende virkning på CYP3A4
English: Pack-size of 56 tablets (multipack carton containing 4 inner cartons of 14 tablets each).
Danish: Blisterpakninger af PVC/PE/PCTFE-aluminiumsfolie.Pakningsstørrelse a 56 tabletter (multipakning med 4 æsker, som indeholder hver14 tabletter).
English: dasabuvir and ombitasvir/paritaprevir/ritonavir without ribavirin or with weight-based ribavirin for 12 weeks
Danish: Behandling: dasabuvir og ombitasvir/paritaprevir/ritonavir uden ribavirin eller med ribavirin baseret på vægt i 12 uger
English: Mechanism: CYP3A4 induction by apalutamide, enzalutamide or mitotane.
Danish: Mekanisme: apalutamid, enzalutamid eller mitotans inducerende virkning på CYP3A4
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV (12 weeks)
Danish: Gruppe A: Dasabuvir og ombitasvir/paritaprevir/ritonavir + RBV (12 uger)
English: NA No dose adjustment required for diazepam; increase dose if clinically indicated.
Danish: (0,73-0,82) Ikke relevant Dosisjustering er ikke nødvendig for diazepam; øgning af dosis, hvis klinisk indiceret.
English: AbbVie B.V. Tel: +31 (0)88 322 2843
Danish: Tel: +31 (0)88 322 2843
English: For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.
Danish: Se beskrivelsen af genotypespecifik aktivitet af hepatitis C-virus (HCV) i pkt.
English: Treated subjects (N = 63) had a median age of 51 years (range: 31 to 69); 24% were Black; 19% had compensated cirrhosis; 67% were treatment-naïve; 33% had failed prior treatment with pegIFN/RBV; 89% had HCV genotype 1a infection.
Danish: I del 1a blev alle forsøgspersoner behandlet med dasabuvir og ombitasvir/paritaprevir/ritonavir med ribavirin i 12 eller 24 uger.De behandlede patienter (N = 63) havde en gennemsnitsalder på 51 år (interval: 31-69), 24 % var sorte, 19 % havde kompenseret cirrose, 67 % var behandlingsnaive, 33 % havde oplevet behandlingssvigt med pegIFN/RBV, og 89 % havde HCV genotype 1a-infektion.
English: 800/160 mg twice daily dasabu vir +
Danish: 800/160 mg to gange dagligt
English: Caution should be used when sulfasalazine is co-administered with dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Danish: Der bør udvises forsigtighed, når sulfasalazin administreres sammen dasabuvir + ombitasvir/paritaprevir/ri tonavir.
English: Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir
Danish: Gruppe B: Dasabuvir og ombitasvir/paritaprevir/ritonavir
English: ↔ digoxin 1.15
Danish: ↑ ciclosporin 1,01
English: The recommended dose of darunavir is 800 mg once daily, without ritonavir, when administered at the same time as ombitasvir/paritaprevir/ ritonavir + dasabuvir (ritonavir dose in ombitasvir/paritaprevir/ ritonavir will provide darunavir pharmacokinetic enhancement).
Danish: Mekanisme: Ikke kendt paritaprevir paritatprevir/ritonavir med dasabuvir (ritonavirdosen i ombitasvir/ paritatprevir/ritonavir forstærker darunavirs farmakokinetik).
English: Exviera contains lactose.
Danish: Exviera indeholder laktose.
English: dasabuvir and ombitasvir/paritaprevir /ritonavir + ribavirin
Danish: Dasabuvir og ombitasvir/paritaprevir /ritonavir + ribavirin
English: IRON CHELATORS Deferasirox dasabu vir + ombitas vir/parit aprevir/ ritonavi r
Danish: JERNCHELERENDE MIDLER Deferasirox Dasabuvir ombitasvir/ paritaprevi r/ritonavir
English: No dose adjustment is necessary for norethindrone or dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Danish: Dosisjustering er ikke nødvendig for norethindron eller dasabuvir med ombitasvir/ paritaprevir/ritonavir.
English: Dasabuvir and ombitasvir/paritaprevir/ritonavir in combination with ribavirin is recommended for 24 weeks in liver transplant recipients.
Danish: Hos patienter med levertransplantat anbefales det at give dasabuvir og ombitasvir/paritaprevir/ritonavir i kombination med ribavirin i 24 uger.
English: For dosing recommendations with calcineurin inhibitors refer to section 4.5.
Danish: 4.5 er der doseringsanbefalinger for calcineurin-hæmmere.
English: As liver function may change during treatment with dasabuvir administered with ombitasvir/paritaprevir/ritonavir, a close monitoring of International Normalised Ratio (INR) values is recommended.
Danish: Tæt monitorering af International Normalised Ratio (INR) værdier anbefales, da leverfunktionen kan ændres under behandling med dasabuvir administreret med ombitasvir/paritaprevir/ritonavir.
English: The EC50 of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays was 7.7 and 1.8 nM, respectively.
Danish: EC50-værdien for dasabuvir mod genotype 1a-H77- og 1b-Con1-stammer i HCV-replikoncellekulturanalyser var henholdsvis 7,7 og 1,8 nM. Dasabuvirs replikon-aktivitet blev 12-13 gange mindre under tilstedeværelse af 40 % humant plasma.
English: When starting coadministration with dasabuvir and ombitasvir/paritaprevir/ ritonavir, give one fifth of the total daily dose of ciclosporin once daily with ombitasvir/ paritaprevir /ritonavir.
Danish: Ved administration samtidig med dasabuvir og ombitasvir/paritaprevir/ ritonavir skal man i starten administrere en femtedel af den samlede
English: THYROID HORMONES Levothyroxin e
Danish: THYROIDEAHORMONER
English: If clinically indicated, higher doses of esomeprazole/lansopraz ole may be needed.
Danish: Brug højere doser esomeprazol/lansoprazol, hvis det er klinisk indiceret.
English: Baseline platelet count, median (× 109/L) < 90, n (%) ≥ 90, n (%) Pooled analyses of clinical trials Durability of response Overall, 660 subjects in Phase 2 and 3 clinical trials had HCV RNA results for both the SVR12 and SVR24 time points.
Danish: I alt havde 660 patienter i kliniske fase 2- og fase 3-studier positive HCV-rna-resultater både ved SVR12- og SVR24-målingerne.
English: Pravastatin 10 mg once daily
Danish: 10 mg én gang dagligt
English: Mechanism: CYP3A4 induction by carbamazepi ne.
Danish: Mekanisme: Carbamazepins inducerende virkning på CYP3A4
English: Mechanism: CYP3A4 inhibition by ritonavir.
Danish: Mekanisme: Ritonavirs hæmning af CYP3A4.
English: dasabu vir +
Danish: Dasabuvir + ↔ R
English: • If you have any further questions, ask your doctor or pharmacist.
Danish: • Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide.
English: Angioedema General disorders and administration and administration site conditions
Danish: Almene symptomer og reaktioner på administrationsstedet Meget almindelig
English: open-label, single-arm, global multicentre
Danish: Forsøgsdesign: åbent, globalt multicenterstudie med en enkelt arm Behandling:
English: NA No dose adjustment needed for sofosbuvir when administered with dasabuvir + ombitasvir/paritaprevir /ritonavir.
Danish: Dosisjustering er ikke nødvendig for sofosbuvir ved samtidig administration med dasabuvir + ombitasvir/paritaprevir/ri tonavir.
English: DIURETICS Furosemide 20 mg single dose
Danish: 20 mg enkeltdosis
English: Smephenytoin Mechanism: CYP2C19 induction by ritonavir.
Danish: Mekanisme: Ritonavirs inducerende virkning på CYP2C19.
English: Medicinal products metabolised by CYP3A4
Danish: Mekanisme: Ritonavirs hæmning af CYP3A4
English: CYP3A by atazanavir and CYP3A inhibition by the additional dose of ritonavir.
Danish: Øget paritaprevireksponering kan skyldes atazanavirs hæmning af OATP1B1/B3 og CYP3A og den yderligere ritonavir-dosis' hæmning af CYP3A.
English: CYP2C8 inhibition and increase in paritaprevir is possibly due to
Danish: Mekanisme: Øget dasabuvireksponering skyldes gemfibrozils CYP2C8hæmning, og øget paritaprevireksponering skyldes muligvis gemfibrozils OATP1B1hæmning.
English: Darunavir/ ritonavir 800/100 mg once daily (administere d in the evening)
Danish: 800/100 mg én gang dagligt (taget om aftenen)
English: Mechanism: P-gp inhibition by dasabuvir, paritaprevir, and ritonavir.
Danish: Mekanisme: Dasabuvirs, paritaprevir og ritonavirs hæmning af P-gp.
English: dasabuvir and ombitasvir/paritaprevir /ritonavir
Danish: Dasabuvir ombitasvir/ paritaprevir /ritonavir
English: dasabu vir + ombitas vir/parit aprevir/ ritonavi r atazanavir
Danish: Dasabuvir + ombitasvir/ paritaprevir/ ritonavir atazanavir
English: Dasabuvir is administered with ombitasvir/ paritaprevir /ritonavir.
Danish: Dasabuvir administreres med ombitasvir/paritaprevir/ritonavir.
English: dasabuvir and ombitasvir/paritaprevir/ritonavir with weight-based ribavirin for 12 or 24 weeks
Danish: Behandling: dasabuvir og ombitasvir/paritaprevir/ritonavir med ribavirin baseret på vægt i 12 eller 24 uger
English: Posology
Danish: Responsvarighed
English: Retreatment
Danish: Gentaget behandling
English: • Itching.
Danish: • kløe.